Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

"The planned regimen for neoadjuvant therapy may include one or more of the following agents:~1. Paclitaxel Injection~2. Albumin-bound paclitaxel Injection (Abraxane® equivalent formulation)~3. Cisplatin Injection~4. Carboplatin Injection~5. Nivolumab~6. Pembrolizumab~7. Toripalimab~8. Tirilibumab~9. Camrelizumab The specific agent(s) and their combination will be selected based on the patient's clinical treatment protocol. The final regimen must be approved jointly by the principal investigator and the attending physician according to established clinical guidelines and individualized patient factors."